Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Gene expression profiles of TNF-like cytokine 1A (TL1A) and its receptors death receptor 3 (DR3) and decoy receptor 3 (DcR3) in multiple sclerosis.

Basnyat P, Sumelahti ML, Lehtimäki T, Elovaara I, Hagman S.

J Neuroimmunol. 2019 Oct 15;335:577020. doi: 10.1016/j.jneuroim.2019.577020. Epub 2019 Aug 14.

PMID:
31445379
2.

Diffusion tensor imaging and disability progression in multiple sclerosis: A 4-year follow-up study.

Kolasa M, Hakulinen U, Brander A, Hagman S, Dastidar P, Elovaara I, Sumelahti ML.

Brain Behav. 2019 Jan;9(1):e01194. doi: 10.1002/brb3.1194. Epub 2018 Dec 26.

3.

Effects of inflammatory cytokines IFN-γ, TNF-α and IL-6 on the viability and functionality of human pluripotent stem cell-derived neural cells.

Hagman S, Mäkinen A, Ylä-Outinen L, Huhtala H, Elovaara I, Narkilahti S.

J Neuroimmunol. 2019 Jun 15;331:36-45. doi: 10.1016/j.jneuroim.2018.07.010. Epub 2018 Aug 29.

PMID:
30195439
4.

Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients.

Vistbakka J, Sumelahti ML, Lehtimäki T, Elovaara I, Hagman S.

Acta Neurol Scand. 2018 Aug;138(2):130-136. doi: 10.1111/ane.12921. Epub 2018 Mar 12.

PMID:
29527713
5.

Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group.

Members of the MS in the 21st Century Steering Group:, Rieckmann P, Centonze D, Elovaara I, Giovannoni G, Havrdová E, Kesselring J, Kobelt G, Langdon D, Morrow SA, Oreja-Guevara C, Schippling S, Thalheim C, Thompson H, Vermersch P, Aston K, Bauer B, Demory C, Giambastiani MP, Hlavacova J, Nouvet-Gire J, Pepper G, Pontaga M, Rogan E, Rogalski C, van Galen P, Ben-Amor AF.

Mult Scler Relat Disord. 2018 Jan;19:153-160. doi: 10.1016/j.msard.2017.11.013. Epub 2017 Nov 21.

6.

JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.

Basnyat P, Virtanen E, Elovaara I, Hagman S, Auvinen E.

J Neurovirol. 2017 Oct;23(5):734-741. doi: 10.1007/s13365-017-0560-x. Epub 2017 Aug 22.

PMID:
28831768
7.

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.

Berger T, Elovaara I, Fredrikson S, McGuigan C, Moiola L, Myhr KM, Oreja-Guevara C, Stoliarov I, Zettl UK.

CNS Drugs. 2017 Jan;31(1):33-50. doi: 10.1007/s40263-016-0394-8. Review.

8.

Circulating microRNAs as biomarkers in progressive multiple sclerosis.

Vistbakka J, Elovaara I, Lehtimäki T, Hagman S.

Mult Scler. 2017 Mar;23(3):403-412. doi: 10.1177/1352458516651141. Epub 2016 Jul 11.

PMID:
27246141
9.

Asymptomatic subjects differ less from their twin siblings with MS than from healthy controls in cognitive functioning. A Finnish Twin Cohort study.

Kuusisto H, Vahvelainen T, Hämäläinen P, Luukkaala T, Elovaara I.

J Neurol Sci. 2016 Jun 15;365:50-3. doi: 10.1016/j.jns.2016.03.046. Epub 2016 Apr 3.

PMID:
27206874
10.

Adipsin Is Associated with Multiple Sclerosis: A Follow-Up Study of Adipokines.

Natarajan R, Hagman S, Hämälainen M, Leppänen T, Dastidar P, Moilanen E, Elovaara I.

Mult Scler Int. 2015;2015:371734. doi: 10.1155/2015/371734. Epub 2015 Nov 8.

11.

[Magnetic resonance imaging of the brain in the monitoring of immune therapy of multiple sclerosis].

Elovaara I, Soilu-Hänninen M, Kuusisto H, Martola J, Tienari P, Färkkilä M, Remes AM.

Duodecim. 2015;131(17):1571-80. Review. Finnish.

PMID:
26548104
12.

Three-decade neurological and neurocognitive follow-up of HIV-1-infected patients on best-available antiretroviral therapy in Finland.

Heikinheimo T, Poutiainen E, Salonen O, Elovaara I, Ristola M.

BMJ Open. 2015 Nov 5;5(11):e007986. doi: 10.1136/bmjopen-2015-007986.

13.

Anti-JC virus seroprevalence in a Finnish MS cohort.

Kolasa M, Hagman S, Verkkoniemi-Ahola A, Airas L, Koivisto K, Elovaara I.

Acta Neurol Scand. 2016 May;133(5):391-7. doi: 10.1111/ane.12475. Epub 2015 Sep 8.

PMID:
26347001
14.

Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.

Basnyat P, Hagman S, Kolasa M, Koivisto K, Verkkoniemi-Ahola A, Airas L, Elovaara I.

Mult Scler Relat Disord. 2015 Jul;4(4):334-8. doi: 10.1016/j.msard.2015.06.008. Epub 2015 Jun 17.

PMID:
26195052
15.

Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group.

Rieckmann P, Boyko A, Centonze D, Elovaara I, Giovannoni G, Havrdová E, Hommes O, Kesselring J, Kobelt G, Langdon D, LeLorier J, Morrow SA, Oreja-Guevara C, Schippling S, Thalheim C, Thompson H, Vermersch P.

Mult Scler Relat Disord. 2015 May;4(3):202-18. doi: 10.1016/j.msard.2015.02.005. Epub 2015 Mar 2. Review.

16.

Analysis of apoptosis-related genes in patients with clinically isolated syndrome and their association with conversion to multiple sclerosis.

Hagman S, Kolasa M, Basnyat P, Helminen M, Kähönen M, Dastidar P, Lehtimäki T, Elovaara I.

J Neuroimmunol. 2015 Mar 15;280:43-8. doi: 10.1016/j.jneuroim.2015.02.006. Epub 2015 Feb 25.

PMID:
25773154
17.

Longitudinal assessment of clinically isolated syndrome with diffusion tensor imaging and volumetric MRI.

Kolasa M, Hakulinen U, Helminen M, Hagman S, Raunio M, Rossi M, Brander A, Dastidar P, Elovaara I.

Clin Imaging. 2015 Mar-Apr;39(2):207-12. doi: 10.1016/j.clinimag.2014.10.014. Epub 2014 Oct 23.

PMID:
25487438
18.

Increasing Incidence in Relapsing-Remitting MS and High Rates among Young Women in Finland: A Thirty-Year Follow-Up.

Sumelahti ML, Holmberg MH, Murtonen A, Huhtala H, Elovaara I.

Mult Scler Int. 2014;2014:186950. doi: 10.1155/2014/186950. Epub 2014 Nov 9.

19.

[Investments of research and treatment of brain diseases will pay of time].

Lindsberg PJ, Castrén E, Korkeila J, Alho H, Erkinjuntti T, Isometsä E, Kalso E, Marttunen M, Pihko H, Tienari P, Wartiovaara A, Jäkälä P, Kälviäinen R, Soininen H, Tiihonen J, Karlsson H, Rinne J, Roine RO, Elovaara I, Tamminen T, Ohman J, Majamaa K, Hari R.

Duodecim. 2014;130(17):1721-30. Review. Finnish.

PMID:
25272783
20.

Impact of atrial fibrillation and inadequate antithrombotic management on mortality in acute neurovascular syndrome.

Saarinen JT, Rusanen H, Sillanpää N, Huhtala H, Numminen H, Elovaara I.

J Stroke Cerebrovasc Dis. 2014 Oct;23(9):2256-64. doi: 10.1016/j.jstrokecerebrovasdis.2014.04.017. Epub 2014 Aug 23.

PMID:
25156784
21.

Hemispheric asymmetry measured by texture analysis and diffusion tensor imaging in two multiple sclerosis subtypes.

Savio S, Hakulinen U, Ryymin P, Hagman S, Dastidar P, Soimakallio S, Elovaara I, Eskola H.

Acta Radiol. 2015 Jul;56(7):844-51. doi: 10.1177/0284185114539323. Epub 2014 Jul 14.

PMID:
25024438
22.

Diffusion Tensor Imaging in NAWM and NADGM in MS and CIS: Association with Candidate Biomarkers in Sera.

Natarajan R, Hagman S, Wu X, Hakulinen U, Raunio M, Helminen M, Rossi M, Dastidar P, Elovaara I.

Mult Scler Int. 2013;2013:265259. doi: 10.1155/2013/265259. Epub 2013 Dec 17.

23.

MR image texture in Parkinson's disease: a longitudinal study.

Sikiö M, Holli-Helenius KK, Harrison LC, Ryymin P, Ruottinen H, Saunamäki T, Eskola HJ, Elovaara I, Dastidar P.

Acta Radiol. 2015 Jan;56(1):97-104. doi: 10.1177/0284185113519775. Epub 2014 Jan 10.

PMID:
24413223
24.

Imaging brain iron and diffusion patterns: a follow-up study of Parkinson's disease in the initial stages.

Rossi ME, Ruottinen H, Saunamäki T, Elovaara I, Dastidar P.

Acad Radiol. 2014 Jan;21(1):64-71. doi: 10.1016/j.acra.2013.09.018.

PMID:
24331266
25.

Increased Female MS Incidence and Differences in Gender-Specific Risk in Medium- and High-Risk Regions in Finland from 1981-2010.

Holmberg M, Murtonen A, Elovaara I, Sumelahti ML.

Mult Scler Int. 2013;2013:182516. doi: 10.1155/2013/182516. Epub 2013 Nov 10. Review.

26.

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D'Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hintzen R, Barcellos LF; Wellcome Trust Case Control Consortium 2 (WTCCC2); International IBD Genetics Consortium (IIBDGC), Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Søndergaard HB, Baker A, Band G, Baranzini SE, Barizzone N, Barrett J, Bellenguez C, Bergamaschi L, Bernardinelli L, Berthele A, Biberacher V, Binder TM, Blackburn H, Bomfim IL, Brambilla P, Broadley S, Brochet B, Brundin L, Buck D, Butzkueven H, Caillier SJ, Camu W, Carpentier W, Cavalla P, Celius EG, Coman I, Comi G, Corrado L, Cosemans L, Cournu-Rebeix I, Cree BA, Cusi D, Damotte V, Defer G, Delgado SR, Deloukas P, di Sapio A, Dilthey AT, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich IY, Galimberti D, Gieger C, Gourraud PA, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt SE, Jagodic M, Jelčić I, Jochim A, Kendall B, Kermode A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay C, Lechner-Scott J, Lee MH, Leone MA, Leppä V, Liberatore G, Lie BA, Lill CM, Lindén M, Link J, Luessi F, Lycke J, Macciardi F, Männistö S, Manrique CP, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero IL, Mescheriakova J, Moutsianas L, Myhr KM, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price SE, Quach H, Reunanen M, Robberecht W, Robertson NP, Rodegher M, Rog D, Salvetti M, Schnetz-Boutaud NC, Sellebjerg F, Selter RC, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen PS, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser EM, Vucic S, Westerlind H, Wiley JS, Wilkins A, Wilson JF, Winkelmann J, Zajicek J, Zindler E, Haines JL, Pericak-Vance MA, Ivinson AJ, Stewart G, Hafler D, Hauser SL, Compston A, McVean G, De Jager P, Sawcer SJ, McCauley JL.

Nat Genet. 2013 Nov;45(11):1353-60. doi: 10.1038/ng.2770. Epub 2013 Sep 29.

27.

Alteration of prolyl oligopeptidase and activated α-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome.

Tenorio-Laranga J, Peltonen I, Keskitalo S, Duran-Torres G, Natarajan R, Männistö PT, Nurmi A, Vartiainen N, Airas L, Elovaara I, García-Horsman JA.

Biochem Pharmacol. 2013 Jun 15;85(12):1783-94. doi: 10.1016/j.bcp.2013.04.018. Epub 2013 Apr 30.

PMID:
23643808
28.

Clinical MRI for iron detection in Parkinson's disease.

Rossi M, Ruottinen H, Soimakallio S, Elovaara I, Dastidar P.

Clin Imaging. 2013 Jul-Aug;37(4):631-6. doi: 10.1016/j.clinimag.2013.02.001. Epub 2013 Mar 20.

PMID:
23522789
29.

Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome.

Comi G, Martinelli V, Rodegher M, Moiola L, Leocani L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Preziosa P, Ravnborg M, Rieckmann P, Rocca MA, Wynn D, Young C, Filippi M.

Mult Scler. 2013 Jul;19(8):1074-83. doi: 10.1177/1352458512469695. Epub 2012 Dec 12.

PMID:
23234810
30.

Volumetric MRI assessment of brain and spinal cord in Finnish twins discordant for multiple sclerosis.

Kuusisto H, Wu X, Dastidar P, Luukkaala T, Elovaara I.

Medicina (Kaunas). 2012;48(9):437-41.

31.

Future MS care: a consensus statement of the MS in the 21st Century Steering Group.

Rieckmann P, Boyko A, Centonze D, Coles A, Elovaara I, Havrdová E, Hommes O, Lelorier J, Morrow SA, Oreja-Guevara C, Rijke N, Schippling S.

J Neurol. 2013 Feb;260(2):462-9. doi: 10.1007/s00415-012-6656-6. Epub 2012 Aug 31.

32.

Location of the clot and outcome of perfusion defects in acute anterior circulation stroke treated with intravenous thrombolysis.

Sillanpää N, Saarinen JT, Rusanen H, Elovaara I, Dastidar P, Soimakallio S.

AJNR Am J Neuroradiol. 2013 Jan;34(1):100-6. doi: 10.3174/ajnr.A3149. Epub 2012 Jun 21.

33.

Melatonin pathway genes are associated with progressive subtypes and disability status in multiple sclerosis among Finnish patients.

Natarajan R, Einarsdottir E, Riutta A, Hagman S, Raunio M, Mononen N, Lehtimäki T, Elovaara I.

J Neuroimmunol. 2012 Sep 15;250(1-2):106-10. doi: 10.1016/j.jneuroim.2012.05.014. Epub 2012 Jun 13.

PMID:
22698518
34.

The mid-M1 segment of the middle cerebral artery is a cutoff clot location for good outcome in intravenous thrombolysis.

Saarinen JT, Sillanpää N, Rusanen H, Hakomäki J, Huhtala H, Lähteelä A, Dastidar P, Soimakallio S, Elovaara I.

Eur J Neurol. 2012 Aug;19(8):1121-7. doi: 10.1111/j.1468-1331.2012.03689.x. Epub 2012 Mar 15.

PMID:
22416757
35.

A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis.

Soilu-Hänninen M, Aivo J, Lindström BM, Elovaara I, Sumelahti ML, Färkkilä M, Tienari P, Atula S, Sarasoja T, Herrala L, Keskinarkaus I, Kruger J, Kallio T, Rocca MA, Filippi M.

J Neurol Neurosurg Psychiatry. 2012 May;83(5):565-71. doi: 10.1136/jnnp-2011-301876. Epub 2012 Feb 22.

PMID:
22362918
36.

Early treatment in multiple sclerosis.

Elovaara I.

J Neurol Sci. 2011 Dec;311 Suppl 1:S24-8.

PMID:
22206762
37.

The clot burden score, the Boston Acute Stroke Imaging Scale, the cerebral blood volume ASPECTS, and two novel imaging parameters in the prediction of clinical outcome of ischemic stroke patients receiving intravenous thrombolytic therapy.

Sillanpaa N, Saarinen JT, Rusanen H, Hakomaki J, Lahteela A, Numminen H, Elovaara I, Dastidar P, Soimakallio S.

Neuroradiology. 2012 Jul;54(7):663-72. doi: 10.1007/s00234-011-0954-z. Epub 2011 Sep 9.

PMID:
21904832
38.

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.

International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatou E, D'alfonso S, Blackburn H, Martinelli Boneschi F, Liddle J, Harbo HF, Perez ML, Spurkland A, Waller MJ, Mycko MP, Ricketts M, Comabella M, Hammond N, Kockum I, McCann OT, Ban M, Whittaker P, Kemppinen A, Weston P, Hawkins C, Widaa S, Zajicek J, Dronov S, Robertson N, Bumpstead SJ, Barcellos LF, Ravindrarajah R, Abraham R, Alfredsson L, Ardlie K, Aubin C, Baker A, Baker K, Baranzini SE, Bergamaschi L, Bergamaschi R, Bernstein A, Berthele A, Boggild M, Bradfield JP, Brassat D, Broadley SA, Buck D, Butzkueven H, Capra R, Carroll WM, Cavalla P, Celius EG, Cepok S, Chiavacci R, Clerget-Darpoux F, Clysters K, Comi G, Cossburn M, Cournu-Rebeix I, Cox MB, Cozen W, Cree BA, Cross AH, Cusi D, Daly MJ, Davis E, de Bakker PI, Debouverie M, D'hooghe MB, Dixon K, Dobosi R, Dubois B, Ellinghaus D, Elovaara I, Esposito F, Fontenille C, Foote S, Franke A, Galimberti D, Ghezzi A, Glessner J, Gomez R, Gout O, Graham C, Grant SF, Guerini FR, Hakonarson H, Hall P, Hamsten A, Hartung HP, Heard RN, Heath S, Hobart J, Hoshi M, Infante-Duarte C, Ingram G, Ingram W, Islam T, Jagodic M, Kabesch M, Kermode AG, Kilpatrick TJ, Kim C, Klopp N, Koivisto K, Larsson M, Lathrop M, Lechner-Scott JS, Leone MA, Leppä V, Liljedahl U, Bomfim IL, Lincoln RR, Link J, Liu J, Lorentzen AR, Lupoli S, Macciardi F, Mack T, Marriott M, Martinelli V, Mason D, McCauley JL, Mentch F, Mero IL, Mihalova T, Montalban X, Mottershead J, Myhr KM, Naldi P, Ollier W, Page A, Palotie A, Pelletier J, Piccio L, Pickersgill T, Piehl F, Pobywajlo S, Quach HL, Ramsay PP, Reunanen M, Reynolds R, Rioux JD, Rodegher M, Roesner S, Rubio JP, Rückert IM, Salvetti M, Salvi E, Santaniello A, Schaefer CA, Schreiber S, Schulze C, Scott RJ, Sellebjerg F, Selmaj KW, Sexton D, Shen L, Simms-Acuna B, Skidmore S, Sleiman PM, Smestad C, Sørensen PS, Søndergaard HB, Stankovich J, Strange RC, Sulonen AM, Sundqvist E, Syvänen AC, Taddeo F, Taylor B, Blackwell JM, Tienari P, Bramon E, Tourbah A, Brown MA, Tronczynska E, Casas JP, Tubridy N, Corvin A, Vickery J, Jankowski J, Villoslada P, Markus HS, Wang K, Mathew CG, Wason J, Palmer CN, Wichmann HE, Plomin R, Willoughby E, Rautanen A, Winkelmann J, Wittig M, Trembath RC, Yaouanq J, Viswanathan AC, Zhang H, Wood NW, Zuvich R, Deloukas P, Langford C, Duncanson A, Oksenberg JR, Pericak-Vance MA, Haines JL, Olsson T, Hillert J, Ivinson AJ, De Jager PL, Peltonen L, Stewart GJ, Hafler DA, Hauser SL, McVean G, Donnelly P, Compston A.

Nature. 2011 Aug 10;476(7359):214-9. doi: 10.1038/nature10251.

39.

Parkinson's disease: interhemispheric textural differences in MR images.

Sikiö M, Holli KK, Harrison LC, Ruottinen H, Rossi M, Helminen MT, Ryymin P, Paalavuo R, Soimakallio S, Eskola HJ, Elovaara I, Dastidar P.

Acad Radiol. 2011 Oct;18(10):1217-24. doi: 10.1016/j.acra.2011.06.007. Epub 2011 Jul 23.

PMID:
21784670
40.

Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: prospective clinical and MRI follow-up study.

Hagman S, Raunio M, Rossi M, Dastidar P, Elovaara I.

J Neuroimmunol. 2011 May;234(1-2):141-7. doi: 10.1016/j.jneuroim.2011.02.009. Epub 2011 Mar 11.

PMID:
21397339
41.

Intravenous immunoglobulins are a therapeutic option in the treatment of multiple sclerosis relapse.

Elovaara I, Kuusisto H, Wu X, Rinta S, Dastidar P, Reipert B.

Clin Neuropharmacol. 2011 Mar-Apr;34(2):84-9. doi: 10.1097/WNF.0b013e31820a17f3.

PMID:
21301327
42.

CT Perfusion ASPECTS in the Evaluation of Acute Ischemic Stroke: Thrombolytic Therapy Perspective.

Sillanpaa N, Saarinen JT, Rusanen H, Hakomaki J, Lahteela A, Numminen H, Elovaara I, Dastidar P, Soimakallio S.

Cerebrovasc Dis Extra. 2011 Jan-Dec;1(1):6-16. doi: 10.1159/000324324. Epub 2011 Feb 17.

43.

Brain iron deposition and sequence characteristics in Parkinsonism: comparison of SWI, T₂* maps, T₂-weighted-, and FLAIR-SPACE.

Rossi M, Ruottinen H, Elovaara I, Ryymin P, Soimakallio S, Eskola H, Dastidar P.

Invest Radiol. 2010 Dec;45(12):795-802. doi: 10.1097/RLI.0b013e3181ec9c96.

PMID:
20829707
44.

Causes of death among patients with multiple sclerosis.

Sumelahti ML, Hakama M, Elovaara I, Pukkala E.

Mult Scler. 2010 Dec;16(12):1437-42. doi: 10.1177/1352458510379244. Epub 2010 Sep 8.

PMID:
20826526
45.

Is the modulatory effect of pregnancy in multiple sclerosis associated with changes in blood apoptotic molecules?

Rinta S, Airas L, Elovaara I.

Acta Neurol Scand. 2010 Sep;122(3):168-74. doi: 10.1111/j.1600-0404.2009.01301.x.

PMID:
20695850
46.

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.

Ravnborg M, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholomé E, Constantinescu CS, Beer K, Garde E, Sperling B.

Lancet Neurol. 2010 Jul;9(7):672-80. doi: 10.1016/S1474-4422(10)70132-0. Epub 2010 Jun 9. Erratum in: Lancet Neurol. 2010 Aug;9(8):759.

PMID:
20542736
47.

MRI texture analysis in multiple sclerosis: toward a clinical analysis protocol.

Harrison LC, Raunio M, Holli KK, Luukkaala T, Savio S, Elovaara I, Soimakallio S, Eskola HJ, Dastidar P.

Acad Radiol. 2010 Jun;17(6):696-707. doi: 10.1016/j.acra.2010.01.005.

PMID:
20457414
48.

[Update on current care guidelines: diagnostics, treatment and rehabilitation of multiple sclerosis].

Elovaara I, Atula S, Erälinna JP, Färkkilä M, Pirttilä T, Remes A, Ruutiainen J, Varis T; Suomalaisen Lääkäriseuran Duodecimin; Suomen Neurologisen Yhdistyksen Asettama Työryhmä.

Duodecim. 2010;126(2):199-200. Finnish.

PMID:
20405605
49.

Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene.

Jakkula E, Leppä V, Sulonen AM, Varilo T, Kallio S, Kemppinen A, Purcell S, Koivisto K, Tienari P, Sumelahti ML, Elovaara I, Pirttilä T, Reunanen M, Aromaa A, Oturai AB, Søndergaard HB, Harbo HF, Mero IL, Gabriel SB, Mirel DB, Hauser SL, Kappos L, Polman C, De Jager PL, Hafler DA, Daly MJ, Palotie A, Saarela J, Peltonen L.

Am J Hum Genet. 2010 Feb 12;86(2):285-91. doi: 10.1016/j.ajhg.2010.01.017.

50.

Can we face the challenge of expanding use of intravenous immunoglobulin in neurology?

Elovaara I, Hietaharju A.

Acta Neurol Scand. 2010 Nov;122(5):309-15. doi: 10.1111/j.1600-0404.2009.01317.x. Review.

PMID:
20085560

Supplemental Content

Loading ...
Support Center